Agilent Technologies Stock News

Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Europe Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering.

Agilent Technologies, Inc. (NYSE:A) CEO Michael R. Mcmullen sold 123,459 shares of the firms stock in a transaction dated Monday, December 20th. The stock was sold at an average price of $148.82, for a total transaction of $18,373,168.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC []

Another factual information on the "Immunoprotein Diagnostic Testing Market" has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various perspectives, for example, global market patterns, pieces of the

DUBLIN, Dec. 23, 2021 /PRNewswire/ -- The "Cannabis Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Type, End User, and Portability and Geography" report has been added to ResearchAndMarkets.com''s offering. According to the study, the market is expected

Nordea Investment Management AB increased its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 100.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 533,634 shares of the medical research company’s stock after purchasing an additional 267,275 shares during the […]

According to the report, The global Next-generation Sequencing (NGS) market size is expected to reach $38.42 Billion by 2028 growing at the CAGR of 18.14% from 2021 to 2028. The major factor driving the growth of the Next-generation Sequencing (NGS)

Whittier Trust Co. of Nevada Inc. increased its holdings in Agilent Technologies, Inc. (NYSE:A) by 65.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,268 shares of the medical research company’s stock after purchasing an additional 503 shares during the quarter. Whittier […] The post Agilent Technologies, Inc. (NYSE:A) Stock Holdings Increased by Whittier Trust Co. of Nevada Inc. appeared first on ETF Daily News .

Immuno Oncology Assays Market: An in-depth analysis of statistics on current and emerging trends provides clarity regarding Immuno Oncology Assays Market dynamics. The report includes Porter''s five forces to analyze the importance of various characteristics such as understanding of suppliers

Agilent Technologies (A) closed at $156.78 in the latest trading session, marking a +1.83% move from the prior day.

Clifford Swan Investment Counsel LLC reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 5.5% in the 3rd quarter, Holdings Channel reports. The firm owned 175,803 shares of the medical research companys stock after selling 10,240 shares during the quarter. Clifford Swan Investment Counsel LLCs holdings in Agilent Technologies were worth $27,612,000 as of its []

Clifford Swan Investment Counsel LLC lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 5.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 175,803 shares of the medical research companys stock after selling 10,240 shares during the quarter. Clifford Swan Investment Counsel LLCs holdings in Agilent Technologies were worth $27,612,000 as []

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Independent Advisor Alliance increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 3.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 9,009 shares of the medical research companys stock after acquiring an additional 278 shares during the period. Independent Advisor Alliances holdings in Agilent Technologies were worth $1,419,000 at the end of []